Pharmacogenetics of Pemetrexed and Carboplatin in Malignant Pleural Mesothelioma Patients
Malignant pleural mesothelioma (MPM) is an aggressive tumor that usually has a poor
prognosis. The combination of cisplatin and pemetrexed has recently become the standard of
care in the first-line treatment of MPM. For patients who are unfit to receive a
cisplatin-based chemotherapy, pemetrexed alone [7] or combined with carboplatin [8] has been
proposed as an alternative treatment choice. The identification of molecular predictors of
effective therapy is important for maximizing therapeutic efficacy and minimizing useless
treatment in cancer patients.
Observational
Observational Model: Cohort, Time Perspective: Retrospective
Evaluate the expression and allelic variants of a panel of candidate genes involved in the resistance to drugs, the genome wide copy number changes in patients treated with drugs combination in the first line
one year
No
Armando Santoro, MD
Principal Investigator
Istituto Clinico Humanitas
Italy: Ministry of Health
ONC/OSS-04/2008
NCT00867711
January 2009
September 2009
Name | Location |
---|